carbostyril has been researched along with Response Evaluation Criteria in Solid Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asou, H; Doi, T; Funai, T; Inoue, K; Kondo, S; Ranka, VK; Tajimi, M; Wacheck, V | 1 |
1 trial(s) available for carbostyril and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinolones; Response Evaluation Criteria in Solid Tumors; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases | 2020 |